Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026
Same author

Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma.

Blood advances·2026
Same author

Beyond biomarkers: tissue still matters.

The Lancet. Haematology·2026
Same author

Photobiomodulation and Wearable Light Therapies: A Bibliometric Analysis of the Scientific Literature (1970-2025).

International journal of environmental research and public health·2026
Same author

SOHO State of the Art Updates and Next Questions | Management of Primary Central Nervous System Lymphoma.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.

Lancet (London, England)·2026

Related Experiment Video

Updated: May 12, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Bendamustine salvage therapy for T cell neoplasms.

Francesco Zaja1, Luca Baldini, Andrés J M Ferreri

  • 1Clinica Ematologica, DISM, Azienda Ospedaliero Universitaria S. M. Misericordia, p.le S. Maria Misericordia 15, 33100, Udine, Italy. zaja.francesco@aoud.sanita.fvg.it

Annals of Hematology
|April 18, 2013
PubMed
Summary

Bendamustine shows promise for treating relapsed/refractory T cell neoplasms, including T cell lymphoma and leukemia. This study found encouraging response rates and survival, warranting further investigation in these challenging cancers.

Related Experiment Videos

Last Updated: May 12, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Area of Science:

  • Hematology
  • Oncology
  • Clinical Research

Background:

  • Relapsed/refractory T cell neoplasms present a significant unmet medical need.
  • Limited effective treatment options exist for these aggressive hematologic malignancies.

Purpose of the Study:

  • To evaluate the efficacy and safety of bendamustine in adult patients with relapsed/refractory T cell neoplasms.
  • To assess response rates, survival outcomes, and adverse events associated with bendamustine treatment.

Main Methods:

  • Retrospective analysis of 20 adult patients with various T cell neoplasms treated with bendamustine.
  • Patient cohorts included T cell lymphoma not otherwise specified (T-NOS), angioimmunoblastic T cell lymphoma (AILT), T prolymphocytic leukemia (T-PLL), mycosis fungoides (MF)/Sézary syndrome (SS), and T cell large granular lymphocytic leukemia (T-LGL).
  • Data collected included response rates (partial response [PR], complete response [CR]), progression-free survival (PFS), overall survival (OS), and toxicity.

Main Results:

  • An overall response rate (ORR) of 55% (45% PR, 10% CR) was observed across all T cell neoplasm subtypes.
  • Specific responses varied by subtype, with notable PRs in T-NOS, T-PLL, MF/SS, and T-LGL, and CRs in AILT and T-LGL.
  • Six-month estimated PFS and OS were 44% and 67%, respectively. Grade 3-4 neutropenia (44%) and thrombocytopenia (25%) were common toxicities, with four major infectious complications reported.

Conclusions:

  • Bendamustine demonstrates activity in relapsed/refractory T cell neoplasms, offering a potential treatment option.
  • The observed response rates and survival data support further investigation of bendamustine in this patient population.
  • Careful monitoring for hematologic toxicities and infectious complications is essential during bendamustine therapy.